Data from the study with the lead ADC candidate, HDP-101, show elimination of tumor cells in one patient Clinical data from IMS will be presented in R&D webinar on 15 October at 17:00 CEST / 11:00 EDT Ladenburg, Germany, 1 October 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today […]
Funds will be used to build out Myricx Bio’s proprietary payload platform and advance its pipeline through clinical proof of concept Novo Holdings Venture Investments Partner Michael Bauer will join Myricx Board of Directors and Principal Max Klement will join Myricx Board as an Observer This is the largest European biotech Series A financing this […]
Raises additional 16M EUR led by Dawn Biopharma, a platform controlled by KKR, with participation from existing investors Funds will be used to further strengthen growing pipeline of first in class ADC assets, including lead asset targeting uPARAP Iyona Rajkomar, Managing Partner at Dawn Biopharma, joins Adcendo Board of Directors Copenhagen, Denmark, May 29th, 2024 – […]
Ladenburg, Germany, 23 May 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that its management team will be participating and presenting on its proprietary ADC technology platforms at the following scientific conferences in May and June in 2024. Read more…
Ladenburg, Germany, 5 April 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that it will be hosting an R&D Webinar on 23 April 2024 at 16.00 CEST/15.00 BST, for investors, analysts and media. The R&D webinar will feature presentations from Heidelberg Pharma’s management […]
